论文部分内容阅读
目的检测抗血管内皮生长因子受体2(VEGFR-2)嵌合Fab抗体对裸鼠肝癌原位移植瘤的治疗作用。方法 40只4周龄雄性BALB/c裸鼠建立肝癌H22细胞移植瘤模型后随机均分为Fab抗体(A)组和生理盐水对照(B)组。比较两组裸鼠生存时间、移植瘤病理变化及微血管密度(MVD)。结果成功建立裸鼠H22肝癌原位移植瘤模型,HE染色显示肝细胞肝癌。A组裸鼠中位数生存时间明显长于B组(20.0dvs.14.0d)(P<0.01);A组肝脏实体瘤内MVD较B组显著减少(8.65±1.79vs.25.64±1.53)(P<0.05)。结论抗VEGFR-2嵌合Fab抗体对裸鼠肝癌原位移植瘤有治疗作用。
Objective To investigate the therapeutic effect of anti-vascular endothelial growth factor receptor 2 (VEGFR-2) chimeric Fab antibody on orthotopic transplanted hepatocellular carcinoma in nude mice. Methods Forty four-week-old male BALB / c nude mice were randomly divided into two groups: control group (A) and saline control group (B). The survival time, pathological changes and microvessel density (MVD) of nude mice in both groups were compared. Results Nude mice H22 hepatoma orthotopically transplanted tumor model was successfully established, HE staining showed hepatocellular carcinoma. The median survival time of group A was significantly longer than that of group B (20.0d vs.14.0d) (P <0.01). The MVD of group A was significantly lower than that of group B (8.65 ± 1.79 vs.25.64 ± 1.53) (P <0.05). Conclusion The anti-VEGFR-2 chimeric Fab antibody has a therapeutic effect on orthotopic transplanted hepatocellular carcinoma in nude mice.